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The emergence of drug resistant strains of Plasmodium spp. creates a critical need for the development of
novel antimalarials. Formation of hemozoin, a crystalline heme detoxiﬁcation process vital to parasite
survival serves as an important drug target. The quinoline antimalarials including chloroquine and amo-
diaquine owe their antimalarial activity to inhibition of hemozoin formation. Though in vivo formation of
hemozoin occurs within the presence of neutral lipids, the lipophilic detergent NP-40 was previously
shown to serve as a surrogate in the b-hematin (synthetic hemozoin) formation process. Consequently,
an NP-40 mediated b-hematin formation assay was developed for use in high-throughput screening.
Here, the assay was utilized to screen 144,330 compounds for the identiﬁcation of inhibitors of crystal-
lization, resulting in 530 hits. To establish the effectiveness of these target-based b-hematin inhibitors
against Plasmodium falciparum, each hit was further tested in cultures of parasitized red blood cells. This
effort revealed that 171 of the b-hematin inhibitors are also active against the parasite. Dose–response
data identiﬁed 73 of these b-hematin inhibitors have IC50 values 65 lM, including 25 compounds with
nanomolar activity against P. falciparum. A scaffold-based analysis of this data identiﬁed 14 primary scaf-
folds that represent 46% of the 530 total hits. Representative compounds from each of the classes were
further assessed for hemozoin inhibitory activity in P. falciparum infected human erythrocytes. Each of
the hit compounds tested were found to be positive inhibitors, while a negative control did not perturb
this biological pathway in culture.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Plasmodium falciparum, the most virulent species of the malaria
parasite, is responsible for nearly one million deaths each year
(2013 World Malaria Report). The overwhelming majority of these
deaths occur among young children residing in sub-Saharan Africa.
Alarmingly, the parasite has developed resistance mechanisms to
nearly all-affordable, widely available antimalarials (Noedl et al.,
2008; Cheeseman et al., 2012). It is therefore critical to enrich
the antimalarial drug discovery pipeline with new chemotypes.
Fortunately, several unique pathways have been identiﬁed that
serve as drug targets including inhibition of DNA synthesis, de
novo heme biosynthesis, glycolysis and hemozoin formation
(Surolia and Padmanaban, 1992; Subbayya et al., 1997; Egan,
2003; Mitra et al., 2012).During the intraerythrocytic stages of infection, the malaria
parasite consumes more than 80% of the infected red blood cell’s
hemoglobin to serve as a source of amino acids (Francis et al.,
1997). This process of hemoglobin degradation occurs within the
parasite’s digestive food vacuole, an acidic organelle (pH 4.8–
5.2). As a consequence of hemoglobin degradation, toxic free heme
is liberated. Lacking an enzymatic method of heme detoxiﬁcation,
the malaria parasite has evolved a method by which it converts
soluble free heme into an insoluble, nontoxic biomineral called
hemozoin, the malarial pigment (Egan, 2008). Though hemozoin
has been studied since the 18th century, it was not until 1999 that
XRD revealed hemozoin consists of a centrosymmetric triclinic unit
cell comprised of reciprocal head-to-tail dimeric units of heme
bound through propionate O-Fe(III) (Pagola et al., 2000). These
heme dimers form an extended crystal structure through hydrogen
bonding of acidic propionic groups from adjacent dimers. The
in vivo mechanism of hemozoin formation has been contested for
many years, though emerging evidence implicates the involvement
of neutral lipids present within the digestive food vacuole as the
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Kapishnikov et al., 2012a,b). Mass spectrometric analysis of the
neutral lipid particles concentrated in the digestive food vacuole
identiﬁed a speciﬁc blend of neutral lipids in a 4:2:1:1:1 ratio of
monostearic, monopalmitic, dipalmitic, dioleic and dilinoleic gly-
cerols (Jackson et al., 2004; Pisciotta et al., 2007). Synthetic neutral
lipid droplets (SNLDs) that consist of this biologically relevant
blend of neutral lipids successfully promote the rapid formation
of b-hematin (half-life of 1.9 ± 0.01 min) under physiological pH
and temperature conditions. Further, soluble free heme was shown
to rapidly partition in the SNLDs in a pH-dependent manner. The
pH proﬁle of heme partitioning resembles that of b-hematin for-
mation (Hoang et al., 2010a,b; Ambele and Egan, 2012). Collec-
tively, this evidence substantiates a role for neutral lipid particles
in the process of hemozoin formation.
As perturbations to hemozoin formation lead to parasite death,
understanding the mechanism of hemozoin formation is useful.
Chloroquine (CQ), one of the most successful antimalarials ever
developed, owes its activity to inhibition of hemozoin formation
(Egan and Marques, 1999; Combrinck et al., 2013). Unfortunately,
the parasite has developed resistance to the use of this quino-
line-based antimalarial. However, this resistance is not due to
changes in the hemozoin formation pathway, but rather arises
from mutations in PfCRT, a membrane protein localized to the
digestive food vacuole (Fidock et al., 2000; Johnson et al., 2004;
Martin et al., 2009). Mutations are thought to be responsible for
reduced accumulation of CQ within the digestive food vacuole,
thereby preventing CQ-heme interactions from occurring. This
efﬂux mechanism is speciﬁc for quinoline-based antimalarials
(Lehane et al., 2008). Consequently, hemozoin formation remains
an important drug target for the development of new non-
quinoline antimalarials.
Recently, the NP-40 b-hematin formation assay was validated
for use in high-throughput screening (HTS). This assay utilizes
the lipophilic detergent, Nonidet P-40 (NP-40), to serve as a surro-
gate for in vitro b-hematin formation under physiologically rele-
vant assay conditions (Fig. 1) (Carter et al., 2010). This detergent
mediator is low cost and requires no special handling steps in
assay setup (Sandlin et al., 2011). Here, the b-hematin formation
assay has been utilized to screen a library of 144,330 commercially
available compounds in the Vanderbilt University Institute of
Chemical Biology (VICB) library (Fig. 2). Each of the target-speciﬁc
hits was analyzed for in vitro antimalarial activity in cultures of P.
falciparum. Follow-up dose–response data was collected for each
in vitro antimalarial compound. Those that exhibited nanomolar
activity against the parasite were further examined in a multi-drug
resistant strain of P. falciparum. The drug target pathway of
hemozoin inhibition was subsequently validated within a chloro-
quine-sensitive strain of P. falciparum to emphasize the biological
relevance of our in vitro target based screen. Scaffold representa-
tives were screened in a culture of P. falciparum infected erythro-
cytes to assess the biological inhibition of heme detoxiﬁcation.2. Materials and methods
2.1. Materials
Nonidet P-40 (NP-40, Shell Chemical Co.) originated from Pierce
Biotechnology, Rockford, Il (not to be confused with different
detergents also referred to as NP-40). Flat bottom, 384-well plates
(3680, Corning) and optical bottom plates (142761, Nunc) were
purchased from Fisher. Hemin (P98%, Fluka), amodiaquine,
sodium acetate trihydrate, saponin, and pyridine were obtained
from Sigma–Aldrich, St. Louis, MO. A (+) human plasma and eryth-
rocytes were purchased from Valley Biomedical, Winchester, VA.SYBR Green-I nucleic acid gel stain (10,000) was supplied by
Invitrogen. The screening library consisted of compounds originat-
ing from ChemBridge and ChemDiv.
2.2. Detergent-mediated NP-40 b-hematin formation assay
The b-hematin formation assay was adapted for use in a 384-
well microtiter plate as previously described (Sandlin et al.,
2011). Solutions were added to the microtiter plate in the order
of water (20 lL), NP-40 stock solution (5 lL), acetone (7 lL), and
heme suspension (25 lL). The NP-40 stock solution (348 lM)
was prepared in water. A 25 mM stock solution of hematin was
prepared by dissolving hemin chloride in DMSO followed by one
minute of sonication. The heme solution was then ﬁltered through
a 0.22 lm PVDF membrane ﬁlter unit. From this solution, the heme
suspension (228 lM) was added to a 2 M acetate buffer at pH 4.9
and vortexed for 5 s. The plate was then incubated for six hours
in a shaking water bath at 45 rpm and 37 C. Following incubation,
the microtiter plate was removed from the water bath and the
assay was analyzed using the pyridine-ferrochrome method
(Ncokazi and Egan, 2005). Following the addition of 15 lL of ace-
tone to each well of the plate, 8 lL of a pyridine solution was added
(50% pyridine, 20% acetone, water and 200 mM HEPES, pH 7.4) so
that the ﬁnal concentration of pyridine was 5% (v/v). Following
30 min of shaking to facilitate the solubilization of free heme, the
absorbance of the resulting complex was measured at 405 nm on
a SpectraMax M5 plate reader.
2.3. Identiﬁcation of b-hematin inhibitors
Test compounds in the Vanderbilt University High-Throughput
Screening Facility originated from ChemBridge and ChemDiv. A
Labcyte Echo 550 non-contact acoustic liquid delivery system
was used to deliver all control and test compounds to the 384-well
assay plate. Positive controls consisted of a 100 lM ﬁnal concen-
tration of amodiaquine (dissolved in DMSO) and negative controls
consisted of DMSO only (0.19%). Controls were added to the ﬁrst
and last two columns of each plate in an alternating, checkerboard
pattern. All test compounds (10 mM in DMSO) were added so that
the ﬁnal test concentration was 19.3 lM (320 total compounds
tested per plate). Following addition of controls and test com-
pounds, the reagents of the b-hematin formation assay described
above were added using a Thermo Scientiﬁc Multidrop Combi Bulk
Reagent Dispenser. Inhibition of b-hematin was assessed relative
to the positive and negative controls on each plate. Compounds
inhibiting P80% b-hematin formation were considered hits. This
stringent threshold for identifying b-hematin inhibitors facilitated
the identiﬁcation of a set of potent inhibitors of crystallization.
Each hit was then tested in duplicate in a dose–response assay to
identify false-positives and establish IC50 values using a range of
concentrations of test compound from 0.5–110 lM. The test com-
pounds were delivered from a 10 mM stock solution in DMSO and
DMSO was backﬁlled to maintain a uniform percentage (0.1%)
throughout the plate. Sigmoidal dose–response curves were gener-
ated using GraphPad Prism v5.0 (March 7, 2007).
2.4. P. falciparum culture conditions
P. falciparum strains D6 (Walter Reed Army Institute of Research
[WRAIR]/Sierra Leone) and C235 (WRAIR/Thailand) were main-
tained using a modiﬁcation of methods described by Trager and
Jensen (1976). RPMI 1640 medium supplemented with 25 mM
HEPES, 11 mM glucose, 0.24% sodium bicarbonate, 10% human A
(+) plasma (heat-inactivated) and 29 lM hypoxanthine was pre-
pared weekly. Cultures were maintained at 5% hematocrit in A (+)
blood (washed two times with RPMI medium and used no longer
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Fig. 1. Workﬂow of the high-throughput b-hematin assay. The 144,330 test compounds were delivered to 384-well microtiter plates using a noncontact liquid handler,
followed the addition of buffer, hemin, and NP-40 detergent (shown) using a bulk liquid delivery system. The plates were incubated while shaking for six hours at 37 C prior
to the addition of pyridine. The absorbance values of the test compounds were read using a SpectraMax M5 plate reader to establish hits of P80% inhibition.
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subcultured upon reaching 5% parasitemia (every 3–4 days). Cul-
tures were incubated at 37 C in a gas mixture of 5% O2, 5% CO2
and N2.
2.5. Malaria SYBR Green I ﬂuorescence (MSF) assay
Inhibitors of b-hematin formation were tested in the CQ-sensi-
tive, D6 strain of P. falciparum using a modiﬁcation of literature
methods (Johnson et al., 2007). Brieﬂy, test compounds were
prescreened at a concentration of 23 lM at 0.3% starting parasite-
mia (2% hematocrit) in duplicate in 384-well optical bottommicro-
titer plates. Positive and negative controls consisted of a kill
concentration of CQ (400 nM in water) and DMSO (0.25%), respec-
tively. Dose–response curves were established for each active
compound from a concentration of 0–23 lM. Sigmoidal dose–
response curves were generated using GraphPad Prism v5.0
(March 7, 2007). Compounds exhibiting nanomolar IC50 values
were further tested in a dose–response format against the multi-
drug resistant C235 strain of P. falciparum.2.6 Heme speciation assay
for target validation
Commercially available hit compounds active both in the
target-based b-hematin assay and the phenotypic MSF assay wereselected from each scaffold and further tested using a protocol
previously described (Combrinck et al., 2013). In short, a culture
of the CQ-sensitive strain D6 consisting of sorbitol synchronized
early ring stage parasites at 5% parasitemia and 2% hematocrit
was evenly divided into four culture ﬂasks and treated with com-
pound. The concentrations chosen were obtained from the results
of the MSF assay and consisted of 0, 0.5, 1, 2, and 3 times the
phenotypic IC50 value of the compound. The cultures were incu-
bated under the conditions described in Section 2.4 for 32 h
before isolating the trophozoites using saponin lysis (0.05%).
The trophozoite pellet was lysed using the freeze-thaw method
followed by addition of HEPES buffer (0.02 M, pH 7.5) and SDS
(4%). After sonication and centrifugation, the supernatant was col-
lected as Fraction 1, while pyridine (5%) was added to the pellet.
A second centrifugation step resulted in collection of the superna-
tant as Fraction 2 and the pellet was solubilized with sodium
hydroxide (0.3 M) as Fraction 3. Each fraction was analyzed by
collecting the absorbance spectra between 300 and 800 nm. The
peak maximum observed at 405 nm was used to calculate the
ratios of heme species: Pf hemoglobin (Fraction 1), intercellular
free heme (Fraction 2), and hemozoin (Fraction 3). Parasite
survival was determined using SYBR Green I ﬂuorescence and
morphological changes were observed using microscopy analysis.
Fig. 2. Workﬂow of the Vanderbilt University Institute of Chemical Biology library
screen. Test compounds were screened for b-hematin inhibition, followed by
testing in vitro antimalarial activity in two strains for Plasmodium falciparum. Hits
from both the primary and secondary screenings will be examined in target
validation and pharmacokinetic studies.
Table 1
The top ten most potent inhibitors of b-hematin formation in the VICB library.
VU identiﬁer Structure b-Hematin IC50 (lM) D6 IC50 (lM)
VU0014981 0.4 Inactive
VU0063871 0.4 Inactive
VU0015078 1.1 0.81
VU0020967 1.5 Inactive
VU0042031 1.7 3.52
VU0000264 2.0 0.59
VU0099210 2.2 Inactive
VU0123869 2.4 Inactive
VU0358176 2.4 1.72
VU0094619 2.4 0.70
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3.1. Identiﬁcation of b-hematin inhibitors
144,330 compounds were tested in the NP-40 b-hematin forma-
tion assay. This screening effort resulted in the identiﬁcation of 729
compounds exhibitingP80% inhibitory activity relative to controls
(0.5% hit rate). This activity threshold ensured that only potent
b-hematin inhibitors were identiﬁed and provided a manageable
number of compounds for follow-up dose response testing. Each
preliminary hit was cherry-picked and tested in a dose–response
assay (0.5–110 lM) to identify false-positives and to establish
the potency of each hit against b-hematin formation. Compounds
exhibiting IC50 values against hemozoin formation of 627 lMwere
conﬁrmed as hits. Using this data approach, a total of 530 hits were
conﬁrmed (0.14% false-positive hit rate), as shown in Supplemen-
tary Data, which will only be available to readers online. All had
IC50 values more potent than CQ (53.0 lM) and 416 were more
potent than AQ (21.0 lM) in this assay. The top ten most potent
b-hematin inhibitors identiﬁed in this screen are shown in Table 1
and highlight the structural diversity resulting from this screening
effort.3.2. Activity of b-hematin inhibitors in cultures of P. falciparum
All conﬁrmed b-hematin inhibitors were counter-screened to
establish whether or not they retained activity in cultures of
P. falciparum parasitized red blood cells, using the in vitro malaria
SYBR Green I ﬂuorescence-based assay (Johnson et al., 2007). Each
b-hematin inhibitor was prescreened at a concentration of 23 lM.
Percent inhibition was determined relative to positive (kill concen-
tration of CQ) and negative (DMSO only) controls. Test compounds
that exhibited P90% inhibition of parasitemia were considered
hits. Using these criteria, 171 of the b-hematin inhibitors identiﬁed
in the primary screen were also active against the parasite cultures.
This high hit rate (32%) was consistent with the pilot screen
(Sandlin et al., 2011).
Follow-up dose–response analysis of the 171 in vitro antimalar-
ial b-hematin inhibitors revealed that 73 compounds exhibited
Table 2
The top ten most potent in vitro antimalarial b-hematin inhibitors identiﬁed. RI = IC50 multidrug-resistant strain/IC50 drug sensitive strain.
VU identiﬁer Structure b-Hematin IC50 (lM) D6 IC50 (lM) C235 IC50 (lM) RI
VU0098755 12.6 0.11 0.13 1.2
VU0073687 6.3 0.18 0.55 2.9
VU0001281 5.9 0.19 0.17 0.9
VU0065708 16.2 0.20 0.18 0.9
VU0096505 8.8 0.24 0.22 0.9
VU0107282 17.0 0.29 0.54 1.9
VU0114785 13.4 0.35 4.82 13.9
VU0002101 14.3 0.35 0.41 1.2
VU0028177 13.3 0.35 0.46 1.3
VU0063971 8.9 0.38 0.83 2.2
320 R.D. Sandlin et al. / International Journal for Parasitology: Drugs and Drug Resistance 4 (2014) 316–32565 lM activity against P. falciparum, including 25 compounds with
nanomolar activity. The ten most potent compounds identiﬁed in
this screen are shown in Table 2. Furthermore, each compound
exhibiting nanomolar activity against the D6 strain was also tested
against the multidrug-resistant C235 strain of P. falciparum. Fol-
lowing the determination of IC50 values in C235, the resistance
index (RI = IC50 multidrug-resistant strain/IC50 drug sensitive
strain) was calculated for each compound to identify those that
are predisposed for resistance (Raynes et al., 1995). For 21 of the
25 nanomolar potent in vitro antimalarials identiﬁed, the calcu-
lated RI was <3, indicating that these compounds are approxi-
mately as effective against drug resistant strains as they are
against sensitive strains. This suggests that the majority of these
compounds can serve as valuable starting points for lead probe
optimization.3.3. Target validation of b-hematin inhibitors in cultures of P.
falciparum through heme speciation
Several representative compounds from each of the scaffold
classes were chosen as exemplars to validate the drug target path-
way within a culture of P. falciparum infected erythrocytes
(Table 3). These b-hematin and parasite inhibitors were tested in
the CQ-sensitive D6 strain at 0, 0.5, 1, 2, and 3 times the IC50 values
obtained in the MSF assay. Through the quantiﬁcation of Pf hemo-
globin, free heme, and hemozoin remaining in the parasite follow-
ing drug treatment, each compound was probed for activity against
the hemozoin formation biological pathway. An increase in para-
sitic free heme concentrations along with a decrease in hemozoin
and parasite survival levels would result in an active inhibitor of
hemozoin formation. Alternatively, if a dose responsive drug
Table 3
Representative hit compounds used for target validation in a parasite culture.
VU identiﬁer Structure Scaffold b-Hematin IC50 (lM) D6 IC50 (lM) C235 IC50 (lM) D Free heme (%)
VU0358505 A 18.1 4.22 ND 10
VU0068286 G 19.1 4.09 ND 8
VU0073687 J 6.3 0.18 0.55 14
VU0077964 K 10.3 3.1 ND 6
VU0054902 B 17.9 4.57 ND 51
VU0122425 D 21.5 4.32 ND 28
VU0118993 E 15.9 9.88 ND 26
VU0099289 N 5.7 9.06 ND 43
VU0065708 H 16.2 0.2 0.18 14
VU0357882 M 8.9 17.83 ND 26
VU0001281 MISC 5.86 0.194 0.174 33
VU0194156 MISC 10.51 6.153 ND 23
Negative control
Not Active 0.99 ND 0.4
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those of an untreated culture, it is likely that the compound does
not target the hemozoin formation pathway. Each of the hits exam-
ined resulted in a rise of free heme relative to hemozoin with
decreased parasite survival, indicating a perturbation of thehemozoin formation pathway. To ensure that the assay is valid, a
compound found to be active against the parasite, but did not inhi-
bit b-hematin formation was used as a negative control. While still
resulting in parasite death, did not show a signiﬁcant difference of
free heme from baseline levels, suggesting another biological drug
A. 10 (5) B. 12 (5) C. 24 (0) 
D. 10 (5) E. 11 (5) F. 13 (8) 
G. 12 (7) H. 8 (4) I. 12 (1) 
J. 19 (9) L. 11 (4) K. 88 (19) 
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Fig. 3. The 14 primary scaffolds identiﬁed in the b-hematin inhibitory screen. Values shown indicate the number of b-hematin inhibitors associated with each scaffold and
the number of those inhibitors that also possess in vitro antimalarial activity (in parentheses).
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be hemozoin inhibitors is again indicative of our biologically rele-
vant NP-40 b-hematin assay. Thus, the results of the heme specia-
tion can give evidence for activity of the remaining hits of our b-
hematin and antimalarial high-throughput screens.
3.4. Structural analysis of hits
In the initial pilot screen of the VICB HTS library, there were six
unique scaffolds identiﬁed as b-hematin inhibitors (Sandlin et al.,
2011). The completed HTS screen reﬁnes the original scaffold
analysis and the 530 hits were binned into categories based upon
a common scaffold. These compounds were identiﬁed from the
dataset using ChemCart by Delta Soft version 5.3, resulting in 14
predominant scaffolds that represent 46% of the total number of
b-hematin inhibitors identiﬁed (Fig. 3). The number of b-hematin
inhibitors associated with each scaffold, as well as the number of
those b-hematin inhibitors that also showed in vitro antimalarial
activity, is shown above each scaffold. A subset of the full VICB
chemical library was used in the pilot screen. The compounds in
this subset were randomly selected and were found to represent
85% of the possible scaffolds available in the entire library. A
complete examination of the library resulted in greater diversity
in structures, as additional scaffolds were found present. The
remaining compounds not falling into one of the 14 scaffolds con-
sist of a variety of chemically distinct structures.4. Discussion
Inhibition of hemozoin formation is an important parasite-
speciﬁc target for the discovery of new antimalarials. Current
evidence suggests neutral lipids as the mediator of hemozoin for-
mation in vivo (Carter et al., 2010; Sandlin et al., 2011;
Kapishnikov et al., 2012a,b). Recently, we have validated an HTS
assay that substitutes the readily available lipophilic detergent,
NP-40, to serve as a surrogate for expensive neutral lipids. Utilizing
the biologically relevant conditions under which hemozoin forma-
tion occurs within the digestive food vacuole of the parasite,
144,330 compounds were screened using the NP-40 b-hematin for-
mation assay. As a result of this effort, 530 b-hematin inhibitors
were identiﬁed. Subsequent dose–response curves revealed that
all of these inhibitors to be more potent than CQ in this assay. Each
of the 530 b-hematin inhibitors was tested in the P. falciparum
assay against the D6 (CQ-sensitive) strain of the parasite to identify
those compounds possessing in vitro antimalarial activity. 32% of
these hits were conﬁrmed to inhibitP90% parasite growth, consis-
tent with trends observed in the pilot screen (Sandlin et al., 2011).
The 25 compounds with nanomolar dose–response activity in the
D6 strain were also tested in the C235 (multidrug-resistant) strain.
Twenty-one of these compounds were as effective against drug
resistant strains as they were against sensitive strains.
Previous successful efforts to identify b-hematin inhibitors in
HTS have been reported (Kurosawa et al., 2000; Rush et al.,
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exhibiting in vitro antimalarial activity resulted from these efforts.
In order to enrich the subset of b-hematin inhibitors that translate
into in vitro antimalarial compounds, the assay utilized here was
designed to mimic the biological conditions where hemozoin
formation occurs. Using an assay design that more faithfully
recapitulates the environment of hemozoin formation, 32% of the
b-hematin inhibitors were found to also kill the parasite. A
previously reported assay utilizing a mechanism dissimilar to the
in vivo process of hemozoin formation resulted in only 3% of
b-hematin inhibitors retaining phenotypic activity (Rush et al.,
2009). Our ﬁndings demonstrate a greater correlation between
b-hematin inhibitory and in vitro antimalarial activity since our
assay more accurately mimics the natural environment of the par-
asite. This retention in activity suggests that higher quality leads
could result from target-based assays if designed to effectively
mimic biological conditions.
Examination of the structures that were identiﬁed as having
activity against b-hematin formation reveals 14 distinct scaffolds
that represent 246 of the total number of compounds identiﬁed
in this screen (Fig. 3). The remaining unassociated 284 compounds
encompass a wide range of structural diversity. While recent phe-
notypic screening campaigns have identiﬁed thousands of active
compounds, their targets have remained largely unknown
(Plouffe et al., 2008; Gamo et al., 2010; Guiguemde et al., 2010).
In the approach taken here, 171 in vitro antimalarial compounds
have been elucidated from an HTS library with their possible target
identiﬁed through probing the hemozoin formation pathway in a
parasite culture. Representatives of each scaffold class were subse-
quently tested in order to validate that they were active against the
putative target, hemozoin. Twelve of the most active, commercially
available compounds were chosen to represent the range of scaf-
fold classes on the hit list. These scaffolds demonstrated a dose
responsive decrease in the parasite’s hemozoin formation with a
concomitant rise in intraparasitic concentrations of free heme.
4.1. Quinoline-based (scaffolds A, G, J and K)
Quinoline-based compounds are among themost successful and
widely used antimalarials developed to date. Though most strains
of the parasite have developed resistance to CQ, several classes of
quinoline derivatives that evade the mechanism of resistance have
been developed including ferroquine which is currently in clinical
development (De et al., 1996; Iwaniuk et al., 2009). The ability to
overcome quinoline resistance suggests that creative medicinal
chemistry could perpetuate quinolines as a valid scaffold. Of the
530 b-hematin inhibitors identiﬁed, several quinoline-based scaf-
folds were noted. Scaffolds A, G, J and K represented 10, 12, 19
and 88 of the total number of b-hematin inhibitors identiﬁed,
respectively. Further, approximately one-third of these quinoline-
based b-hematin inhibitors were active against the parasite. While
scaffold A was previously reported in the results of the pilot screen
(38,400 compounds were screened), scaffolds G, J and K were only
identiﬁed after completion of screening the entire VICB HTS library
(Sandlin et al., 2011). Derivatives of scaffold G have previously been
reported in the PubChem database (http://pubchem.ncbi.nlm.nih.
gov/) as having activity against P. falciparum targeting M18 aspartyl
aminopeptidase (AID 1822), plastid activity (AID 504834) and glu-
cose-6-phosphate dehydrogenase activity (AID 504690). Scaffold G
is of particular interest as it has been shown previously to possess
activity against P. falciparum gametocytes (AID 743093), suggesting
a possible therapeutic strategy that would target multiple stages of
the parasite life cycle. Recently scaffold K was determined to have
activity against multiple strains of P. falciparum (AID 743322,
743323, 743324,). Quinolines have previously been linked to car-
diotoxicity (White, 2007). Therefore, it will be critical to evaluatethe cardiotoxic potential of each quinoline scaffold prior to pursu-
ing them as valuable starting points for lead optimization. When
the quinoline scaffoldwas examined for biological target validation,
each of the representative compounds chosen exhibited activity
against the hemozoin formation pathway. Notably, each of the
quinolines tested required only a slight increase in free heme con-
centration in order to cause a signiﬁcant decrease in parasite sur-
vival. This low requirement compared to other structures may be
indicative of the potency of the quinoline scaffold to create toxic
effects. Mechanistic studies are ongoing to understand how quino-
line compounds perturb the hemozoin formation pathway.
4.2. Phenyl benzamides (scaffolds B, D and E)
Phenyl benzamides were also identiﬁed from the results of the
HTS effort, a scaffold not previously recognized in the pilot screen
(Sandlin et al., 2011). Benzamides have previously been investi-
gated for their activity against P. falciparum (AID 2306) and have
also been identiﬁed as inhibitors of the P. falciparum pyrimidine
biosynthetic enzyme dihydroorotate dehydrogenase PfDHODH
(Heikkila et al., 2007; Jung et al., 2009; Guiguemde et al., 2010;
Sandlin et al., 2011). Scaffolds B, D and E contained 12, 10 and 11
b-hematin inhibitors, respectively, with IC50s ranging from 5.0 to
24.4 lM. Surprisingly, nearly half (45%) of these phenyl benzamide
b-hematin inhibitors were also active in parasite cultures exhibit-
ing IC50s between 0.35 and 16.1 lM. Three compounds were used
as exemplars for these scaffolds to test for perturbation of the
hemozoin formation pathway within a parasite culture, each of
which were found to be active. As opposed to the quinoline scaf-
fold discussed in Section 4.1, these compounds resulted in drastic
increases of intracellular free heme levels corresponding to para-
site death. These differences may be due to the speciﬁc interactions
of the compound with free heme or the hemozoin crystal and are
currently being investigated.
4.3. Benzylethene (scaffolds A and I)
Scaffolds A and I contain an ethene-bridged phenyl group to
either a quinoline or benzimidazole. Scaffolds A and I contained
10 and 12 compounds, respectively. 50% of scaffold A b-hematin
inhibitors were active against the parasite while 8% of the b-hema-
tin inhibitors from scaffold I were active against the parasite.
Though A is an 8-hydroxyquinoline (and by structural deﬁnition
is a quinoline), the quinoline portion of this scaffold does not
explain its activity. Previous analysis of 8-hydroxyquinoline has
demonstrated that this compound is not active against b-hematin
formation (Sandlin et al., 2011). Therefore, the activity of scaffold
A must be related to the addition of the ethene-bridged phenyl
group. As such, it is more accurate to group scaffold A with scaffold
I than to associate it strictly with the quinoline chemotype. While
the two scaffolds, A and I, containing this structural motif have pre-
viously been reported to have in vitro antimalarial activity (AID
2306) (Guiguemde et al., 2010) and to inhibit both the M1 alanyl
aminopeptidase (AID1445) and the M17 leucine aminopeptidase
targets (AID 1619).
4.4. Triaryl imidizole (scaffold N)
The triaryl imidazole scaffold has been shown to exhibit anti-
bacterial and analgesic activity and to have high in vitro antimalar-
ial activity (Khan et al., 2008; Sandlin et al., 2011). However, prior
to this study the mechanism of interaction with heme as a drug
target has not been explored. The screening efforts yielded seven
triaryl imidazoles with IC50 values ranging from 2.4 to 22.9 lM,
six of these possessing in vitro antimalarial activity consisting of
IC50 values between 0.61 and 11.7 lM. Recent phenotypic screens
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compounds of the triaryl imidazole scaffold to have IC50 values of
less than 1 lM (Plouffe et al., 2008; Gamo et al., 2010). No previous
reported target activity for scaffold N was found for P. falciparum.4.5. Miscellaneous Compounds
In addition to the 14 scaffolds identiﬁed in this effort, a large
number of interesting compounds were not associated with a
speciﬁc scaffold type, or only accounted for a very small percentage
of the overall hit rate. Speciﬁcally, 284 b-hematin inhibitors that
did not fall into a speciﬁc scaffold were identiﬁed including 92
in vitro antimalarial compounds. The structural diversity of these
compounds includes pyridines, amides, indoles, acridinediones,
amides, ethers and thiols, among others. Importantly, the majority
of these compounds have not previously been reported as inhibi-
tors of b-hematin formation. A search through the PubChem
database of previous screens revealed overlap in activity in
multiple strains of P. falciparum not only within scaffolds, but
also for unique compounds. Of particular interest is VU0015069,
as it is not only an in vitro antimalarial and b-hematin inhibitor
(IC50 = 1.90 lM and 10.4 lM, respectively), but in a previous screen
was found to inhibit the development of the apicoplast in P. falci-
parumwith a reported potency of 6.57 lM (AID 504832). Since this
compound (CID 2842454) inhibits two separate P. falciparum target
pathways, it is more likely to be a highly effective drug and should
be made a priority for future target validation and pharmacokinetic
studies.5. Conclusion
HTS has become a valuable technique to rapidly identify in vitro
antimalarial compounds. Notably, GSK, St. Jude Children’s Research
Hospital and Novartis have screened millions of compounds
against P. falciparum (Plouffe et al., 2008; Gamo et al., 2010;
Guiguemde et al., 2010). Despite these screens resulting in thou-
sands of in vitro antimalarials, there is still a challenge in optimiz-
ing these lead compounds since their targets are unknown. The
reductionist approach reported herein facilitates the prioritization
of HTS in vitro antimalarial compounds based on their activity
against a speciﬁc antimalarial target, hemozoin formation. This
biological target pathway can be validated in P. falciparum through
the quantitation of Pf hemoglobin, free heme, and hemozoin as
previously described (Combrinck et al., 2013). Representative com-
pounds from each of the scaffold classes were tested as a small
subset of the entire hit list, resulting in the conﬁrmation of the per-
turbation of the hemozoin formation pathway. Concurrently, all hit
compounds are being examined for cytotoxicity in theWRAIR RAW
264.7 cytotoxicity screen. An initial examination of 35 hits active
against both in vitro b-hematin inhibition and parasites showed
that 33 of 35 were non-toxic up to 20 lM (Sandlin et al., 2011).
Once compounds have been identiﬁed to inhibit the b-hematin
pathway and pass the cytotoxicity screen, they will be tested fur-
ther in terms of solubility, permeability and metabolic stability.
With such a diverse library of compounds, the probability of iden-
tifying multiple lead candidates for further development is strong.Acknowledgements
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